CLINICAL TRIALS PROFILE FOR TRIENTINE TETRAHYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for trientine tetrahydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004339 ↗ | Study of Tetrathiomolybdate in Patients With Wilson Disease | Completed | University of Michigan | Phase 3 | 1994-01-01 | OBJECTIVES: Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with trientine therapy as initial treatment in patients with Wilson disease presenting neurologically. |
| NCT00004339 ↗ | Study of Tetrathiomolybdate in Patients With Wilson Disease | Completed | National Center for Research Resources (NCRR) | Phase 3 | 1994-01-01 | OBJECTIVES: Evaluate the safety and efficacy of ammonium tetrathiomolybdate alone and compared with trientine therapy as initial treatment in patients with Wilson disease presenting neurologically. |
| NCT00212355 ↗ | Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan. | Completed | Nobelpharma | Phase 3 | 2005-03-01 | The purpose of this long-term study is to determine whether Zinc Acetate is effective and safe in the treatment of Wilson's disease among Japanese. |
| NCT01178112 ↗ | Trientine and Carboplatin in Advanced Malignancies | Completed | M.D. Anderson Cancer Center | Phase 1 | 2010-07-01 | The goal of this clinical research study is to find the highest tolerable dose of the combination of trientine and carboplatin that can be given to patients with advanced cancer. The safety of this drug combination will also be studied. |
| NCT01213888 ↗ | Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy | Terminated | University of British Columbia | N/A | 2010-11-01 | To evaluate the effects of Trientine Hydrochloride in prevention of post-laser (pan-retinal photocoagulation) macular edema in the eyes for subjects with diabetic retinopathy. Trientine hydrochloride can limit secondary inflammatory damage to retinal vessels following the administration of pan-retinal photocoagulation therapy for severe non-proliferative diabetic retinopathy or retinal neovascularization due to diabetic retinopathy, resulting in less macular edema and improved visual outcomes. |
| NCT01295073 ↗ | Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus | Withdrawn | University of British Columbia | Phase 2 | 1969-12-31 | The primary purpose of the protocol is to evaluate whether Trientine Hydrochloride, a copper chelator which is an agent that binds with and removes copper, will be effective in minimizing macular edema after cataract surgery in individuals with type 2 diabetes. It is our hypothesis that there will be a reduction in copper-attributed inflammation after surgery resulting a decrease in edema. |
| NCT01472874 ↗ | Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease | Completed | Bausch Health Americas, Inc. | N/A | 2010-01-01 | Hypothesis: The investigators postulate that patients with Wilson disease who are asymptomatic or who have been effectively treated for their symptoms and are in a maintenance phase therapy can be safely and effectively treated with a single daily dosage of the chelating agent trientine. Specific Aims: To demonstrate that a single daily treatment with trientine is as effective or better than a patient's current maintenance therapy. This will be accomplished by performance of a case control prospective study of patients on their prior therapy, and during a period of treatment with a single weight based dose regimen of trientine. The primary endpoint for this study is the demonstration of equivalence to a patient's prior therapy. Secondary endpoints include: 1) demonstration of stability or improvement in parameters of copper metabolism; 2) improvement in adherence to therapy; 3) no progression of liver disease (defined by changes in synthetic function, albumin and INR, and fibrosis by Fibrotest). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for trientine tetrahydrochloride
Condition Name
Clinical Trial Locations for trientine tetrahydrochloride
Trials by Country
Clinical Trial Progress for trientine tetrahydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for trientine tetrahydrochloride
Sponsor Name
